Free Trial

John Newman Analyst Performance

Analyst at Canaccord Genuity Group

John Newman is a stock analyst at Canaccord Genuity Group focused in the medical sector, covering 46 publicly traded companies. Over the past year, John Newman has issued 9 stock ratings, including buy and hold recommendations. While full access to John Newman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights John Newman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
392 Last 11 Years
Buy Recommendations
90.54% 354 Buy Ratings
Companies Covered
46 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy90.5%354 ratings
Hold9.5%37 ratings
Sell0.0%0 ratings

Out of 391 total stock ratings issued by John Newman at Canaccord Genuity Group, the majority (90.5%) have been Buy recommendations, followed by 9.5% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
89.1% of companies on NASDAQ
41 companies
NYSE
8.7% of companies on NYSE
4 companies
PINK
2.2% of companies on PINK
1 company

John Newman, an analyst at Canaccord Genuity Group, currently covers 46 companies listed on NASDAQ, NYSE and PINK, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
40 companies
87.0%
Miscellaneous
4 companies
8.7%
Finance
1 company
2.2%
Business Services
1 company
2.2%

John Newman of Canaccord Genuity Group specializes in stock coverage within the Medical sector, with additional focus on and Finance companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
16 companies
34.8%
PHARMACEUTICAL PREPARATIONS
13 companies
28.3%
MED - DRUGS
4 companies
8.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
4 companies
8.7%
Miscellaneous
4 companies
8.7%
BIOTECHNOLOGY
2 companies
4.3%
FIRE, MARINE, & CASUALTY INSURANCE
1 company
2.2%
GOVERNMENT SERVICES
1 company
2.2%
MED - GENERIC DRG
1 company
2.2%

John Newman's Ratings History at Canaccord Genuity Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Merus N.V. stock logo
MRUS
Merus
9/29/2025Downgrade$93.56$97.00Hold
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
9/24/2025Boost Price Target$17.56$22.00Buy
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7/23/2025Reiterated Rating$572.92$850.00Buy
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
3/14/2025Reiterated Rating$1.90$14.00Buy
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3/11/2025Reiterated Rating$6.16$17.00Buy
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
3/11/2025Reiterated Rating$103.54$171.44Buy
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3/5/2025Initiated Coverage$1.38$8.00Buy
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2/19/2025Initiated Coverage$9.52$20.00Buy
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
1/17/2025Lower Price Target$6.88$17.00Buy